Canada’s Energy Stocks On Fire Today – And One Tiny Biotech That Could Beat the Heat

A 3D-printed oil pump jack in front of the OPEC logo. Global oil dynamics are fueling trading activity in Canadian energy stocks.

The Canadian stock market is ablaze with energy optimism today (October 1, 2025). Heavyweight oil and gas stocks are dominating trading screens, buoyed by robust volume and investor enthusiasm. Canadian Natural Resources, Tourmaline Oil, and Suncor Energy – pillars of Canada’s energy sector – are among the most active tickers on the TSX, riding a wave of sector momentum despite choppy crude prices. Even Bitfarms Ltd., a crypto-miner often grouped with tech, is surging in sympathy with spiking Bitcoin prices. In the midst of this energy euphoria, one unlikely outlier beckons: Hemostemix (TSXV: HEM), a little-known biotech microcap. Below, we break down the day’s hottest Canadian stocks and why this speculative biotech could offer a clever diversification play against energy volatility.

Canadian Natural Resources (TSX: CNQ) – Oil Sands Giant Powers Ahead

Canadian Natural Resources (CNQ) is grabbing headlines and trading volume on the TSX today. The stock recently broke above its 200-day moving average, hitting a multi-month high of about C$45.04 during Tuesday’s session. As of midday, CNQ was trading around the mid-$44 range on robust volume – nearly 9.5 million shares changed hands on Tuesday alone, underscoring intense investor interest. With a market capitalization near C$93 billion, CNQ’s sheer size makes it a bellwether for the entire Canadian oil patch.

Price Action: Even as oil prices have seesawed (Brent around the mid-$60s per barrel amid OPEC+ supply headlines), CNQ’s stock has shown resilience. It finished last quarter at record levels, helping lift the TSX to an all-time high above 30,000 points. Traders are now positioning for CNQ’s next move, eyeing its technical breakout above long-term averages as a bullish signal.

Catalysts: Analysts remain broadly positive – CNQ carries a “Moderate Buy” consensus with an average target price of ~C$54.75, implying further upside. The company’s strength lies in its massive oil sands operations and diversified production (from heavy oil to natural gas), which generated gushing cash flows when crude prices were higher last year. Notably, CNQ is a shareholder darling for dividends, recently paying out C$0.5875 per share quarterly, and yielding roughly ~5% at current prices. This hefty payout is well-supported by cash flows, making CNQ attractive to income investors even during oil price volatility. With a fortress balance sheet and low decline rates on its long-life reserves, CNQ is viewed as a relatively defensive play in a cyclical sector. Today’s active trading suggests investors are rotating into this “oilsands king” on any dips, banking on its stability and momentum from recent tailwinds (like interest rate cuts and a strong Q3 for commodities).

Tourmaline Oil (TSX: TOU) – Natural Gas Leader in the Spotlight

Tourmaline Oil (TOU), Canada’s largest natural gas producer, is another top trader on the TSX today, albeit for slightly different reasons. The stock saw high volatility this week after a prominent analyst downgrade: TD Securities cut Tourmaline to “Hold” and trimmed its price target, prompting a 4% drop to about C$60.20 during yesterday’s trading. That dip, the sharpest in the TSX energy cohort, put Tourmaline squarely in focus for bargain hunters today. By midday, TOU shares were stabilizing in the low C$60s on solid volume (over 1.7 million shares traded during Tuesday’s session), as investors digested the news.

Price Action: Prior to the pullback, Tourmaline had been on an upswing, supported by strong operational results and hefty shareholder payouts. The company declared a special dividend of C$0.50 per share in September, on top of its regular dividends, rewarding shareholders from its gushing free cash flow. Even after the recent dip, Tourmaline’s stock is up over the past year and trading not far from its 52-week high (~C$70.83). The sudden downgrade-induced selloff appears to be a short-term speedbump, as fundamentals remain strong – a fact not lost on insiders.

Catalysts: Insider buying has been a vote of confidence here. In late August, a Tourmaline director scooped up 17,000 shares at ~$58.30, a ~$1 million purchase, signaling that management sees value in the stock. Tourmaline is prized for its exposure to natural gas at a time when LNG export projects promise future demand. Any spike in gas prices (for instance, during a cold winter) could send TOU climbing. Moreover, Tourmaline’s lean operations and low debt (debt-to-equity ~10%) give it flexibility to continue returning cash through dividends and buybacks. The company’s market cap around C$23 billion places it among the top-tier Canadian energy firms, and it sports a reasonable P/E of ~15, suggesting it’s not overvalued.

Suncor Energy (TSX: SU) – Oil Sands to Gas Pumps, This Integrated Gusher Attracts Income Investors

Suncor Energy (SU), another heavily traded large-cap, is benefiting from today’s bullish tone in Canadian energy. By midday, Suncor’s stock was holding steady in the high C$ Fifty-something range (around C$57-58 per share), roughly flat to slightly up despite oil’s mild pullback. What Suncor may lack in flashy intraday moves, it makes up for in steady investor interest – it consistently ranks among the TSX’s most active names (averaging 14+ million shares in daily volume). With a market cap near C$71 billion, Suncor is a staple in portfolios, especially for dividend seekers and those looking for an energy play with a twist of stability.

Operations & Catalysts: As an integrated energy company, Suncor isn’t just about pumping oil – it also refines crude and sells gasoline through its Petro-Canada stations. This integration acted as a buffer recently: even as upstream earnings were pressured by year-over-year oil price declines, downstream refining profits helped. Suncor’s upstream production hit record highs earlier in 2025, yet second-quarter earnings fell, reflecting narrower margins. In response, the company doubled down on shareholder returns and efficiency. Under new leadership (CEO Rich Kruger, appointed 2023, known for emphasizing operational safety and reliability), Suncor has streamlined projects and cut costs. It completed a C$1.25 billion share buyback program and continues to pay a juicy dividend of ~3.9% yield – about C$0.52 quarterly per share. That payout is well-covered (49.5% of earnings) and was even hiked in recent years after a brief cut in 2020, signaling renewed confidence in cash flows.

Today’s Drivers: Investors see Suncor as a relatively defensive play in the energy space. The stock’s inclusion in many dividend and index funds means it gets steady inflows. Today’s market narrative of a “bullish energy sector” has naturally swept up Suncor – it’s a go-to name when allocators increase energy exposure. Moreover, any positive sentiment around oil sands (such as improved transportation or export capacity) tends to lift SU. While oil prices are off their highs, they remain at levels where Suncor is highly profitable, especially given improvements in its cost structure. Suncor’s refining segment also can benefit from oil price volatility, as lower crude input costs sometimes boost refining margins – a dynamic that may be in play if the current oil dip persists.

Bitfarms Ltd. (TSX: BITF) – Crypto Miner Riding the “Uptober” Wave

In an intriguing twist, a crypto mining stock has joined the ranks of today’s hottest Canadian “energy” plays. Bitfarms (BITF), primarily known as a Bitcoin miner, is surging in trading as Bitcoin’s price skyrockets to new heights. The world’s largest cryptocurrency just blasted above US$116,000 – kicking off what traders dub “Uptober” with a bang. This crypto rally has spilled into equities, and Bitfarms is a prime beneficiary. The stock jumped roughly 3% in pre-market and early trading today, hitting around C$3–4 per share (its highest levels in years, after a multi-month run-up).

Price & Volume: Bitfarms’ move may seem modest in percentage terms, but consider that the stock had already climbed dramatically in recent weeks. Just a month ago, BITF was trading near C$1.5–2.0; by late September it peaked around C$4.78. On September 23, Bitfarms saw 3.57 million shares trade (about 24% above its average volume) as it closed at C$3.95. That marked a massive upswing – the 50-day average price was only C$2.07, reflecting how sharply the stock has rallied alongside Bitcoin. Today’s continued climb on heavy volume suggests momentum traders are still very much in play. Bitfarms’ market cap neared C$2 billion during the recent highs, qualifying it as a mid-cap and putting it on more investors’ radar.

Catalysts: The driver here is straightforward – Bitcoin’s bull run. With BTC crossing $116k and even eyeing $120k+, every crypto-linked stock is catching a bid. Bitfarms, which operates mining farms in Canada, the U.S. and Latin America, effectively acts as a leveraged play on Bitcoin prices. When Bitcoin rises, Bitfarms’ mining revenues and asset values (they hold some BTC) typically surge. The company has also expanded capacity, meaning any increase in crypto prices can materially boost output. Importantly, investor sentiment has turned euphoric in the crypto space this month – evidenced by terms like “Uptober.” That sentiment is fueling speculative flows into stocks like BITF.

However, risks and recent developments merit a mention. Bitfarms’ volatile run attracted some profit-taking: insiders sold ~507,000 shares over the past 90 days, including a block at C$4.78 (near the peak). The firm carries debt (debt-to-equity ~4.68) and no earnings (negative P/E), so this is a pure play on crypto prices rather than fundamentals. Still, with Bitcoin mining stocks collectively hitting a record market cap and mainstream interest growing in crypto (talk of Bitcoin ETFs, etc.), Bitfarms remains in the limelight.

Hemostemix (TSXV: HEM) – A Biotech Wildcard as a Non‑Correlated Alternative

Shifting gears from multi-billion-dollar energy giants, we turn to Hemostemix (HEM) – a tiny biotech on the TSX Venture Exchange that’s largely under the radar. Why talk about a sub-$20 million market cap company on a day when oil stocks are stealing the show? Because Hemostemix represents the polar opposite of an oil producer, and thus a potential non-correlated play for diversification. When energy stocks gyrate on oil prices or macro news, a clinical-stage biotech like HEM marches to a different drumbeat – its fortunes hinge on scientific and regulatory milestones. Not only that, Hemostemix has had some intriguing developments recently that savvy investors are watching.

Recent Price Performance: HEM’s stock is trading around $0.10 per share (yes, ten cents), after a modest rise over the summer. It’s still a penny stock, but notably off its lows – earlier this year it was as low as $0.06, and it hit a 52-week high of $0.425 during a speculative surge. In the past three months, average volume was only ~234,000 shares a day (sometimes just tens of thousands of dollars changing hands), which is peanuts compared to the multi-million share days for TSX large caps. Market capitalization sits around C$19 million at current prices. All this underscores how microscopic Hemostemix is relative to the CNQs and Suncors of the world. Yet, that small size also means the stock can be explosive on any positive news – and some news has indeed been percolating:

• Regulatory Game-Changer (Early Revenue Potential): In July 2025, Florida passed Senate Bill 1768, a law allowing the sale of certain experimental stem cell therapies in the state with patient consent. Hemostemix’s lead therapy **ACP-01 (branded “VesCell”) – an autologous stem-cell treatment for ischemic diseases – became eligible for commercial use in Florida immediately under this law. The company hailed this as a landmark opportunity, planning to treat its first paying patients by Q4 2025 and projecting $22.5 million in sales in 2026 from the Florida market. In essence, Hemostemix found a way to generate revenue before full FDA approval by leveraging Florida’s progressive stance on regenerative medicine. This is highly unusual (biotechs typically burn cash for years in trials), and it sent a jolt of optimism through its investor base mid-year.
• Clinical Progress & Data: Hemostemix has completed a Phase II trial for critical limb ischemia (a severe artery blockage condition) with promising results. Published data showed significant healing – e.g., leg ulcers shrinking dramatically in treated patients vs. placebo – and lower amputation and mortality rates for patients on ACP-01. Over 500 patients have been treated with ACP-01 compassionate therapies to dat, establishing a safety profile. These outcomes, presented in journals and conferences, bolster Hemostemix’s scientific credibility and support its push to eventually win FDA approval. In the meantime, real-world patient testimonials and case studies (some Floridians have no other options for limb-saving treatment) create a compelling human-interest angle that can attract speculative investors.
• Insider & Financial Backing: In a show of confidence, Hemostemix’s insiders and strategic investors recently put significant skin in the game. Over the summer, the company raised $2.7 million in an oversubscribed private placement at $0.10 per unit – effectively at the market price, indicating investors were willing to buy in without a discount. Notably, the Chairman, Peter Lacey, personally led with a $1.5 million investment in that round. Several directors joined as well. This infusion not only provided vital working capital (funding ongoing operations and the commercial rollout of VesCell™ in Florida), but also signaled insiders’ belief in the company’s trajectory. Furthermore, Hemostemix negotiated a debt settlement at $0.20 per share – creditors accepting stock at double the market price – which cleaned up the balance sheet and underscored external confidence in its future prospects. Such insider buying and friendly debt deals are typically viewed as bullish indicators in microcaps.

In short, Hemostemix offers a completely different risk-reward profile compared to the big energy stocks. It is high risk (as a penny-stock biotech with no guaranteed revenue and ongoing need for regulatory approvals), and its stock can be very illiquid and volatile. However, its fate doesn’t depend on oil, interest rates, or the broader economic cycle – instead, it hinges on medical breakthroughs and niche legislation. That means a portfolio including HEM alongside energy names might enjoy some hedge: days when oil stocks sink on OPEC news could be the very days a stock like HEM jumps on a trial update (or vice versa). Indeed, Hemostemix’s recent developments (Florida law, trial results, insider buys) have started to garner attention on Bay Street as a speculative play. At around 10 cents, the stock is cheap enough that even a small allocation can potentially yield outsized returns if the company’s therapy gains traction (for example, achieving that forecasted $22M in sales would be extraordinary relative to its sub-$20M market cap). It’s worth noting, though, that HEM’s non-correlation cuts both ways – it won’t ride the coattails of an oil rally, and it carries its own set of biotech-specific risks.

Summary: Balancing Energy Windfalls with Biotech Upside

Today’s market action in Canada highlights the booming confidence in large-cap energy stocks. Names like CNQ, Tourmaline, and Suncor are surging or trading actively on bullish catalysts – from strong oil/gas fundamentals to technical breakouts and big capital returns – making them attractive for investors seeking momentum and yield. Even a crypto proxy like Bitfarms has joined the party, reminding us that opportunistic gains can come from unexpected corners when the macro winds (in this case, Bitcoin’s rally) blow favorably.

However, as any seasoned investor knows, diversification is key, especially in volatile sectors. This is where considering an entirely different asset, such as an emerging biotech like Hemostemix, can be valuable. Hemostemix’s fortunes don’t rise and fall with oil prices; they depend on clinical success and regulatory changes, which means the stock may zig when oil stocks zag. By pairing some of the “sure thing” strength of large-cap energy (with their robust cash flows, dividends, and correlation to economic growth) with a small allocation to high-upside, non-correlated plays like HEM, investors can aim to smooth out portfolio volatility. The energy names provide stability and income, while the biotech microcap injects an element of growth speculation that could pay off independently of oil’s trajectory.

In essence, Canada’s bullish energy sector and speculative biotech scene need not be mutually exclusive. An investor can enjoy the dividends and gains from oil and gas high-fliers and keep an eye on groundbreaking healthcare developments. The two categories counterbalance each other – one grounded in today’s commodity-driven cash generation, the other reaching for tomorrow’s medical breakthroughs. As evidenced by the market’s movers on this October day, opportunity exists at both ends of the spectrum. Savvy investors may choose to ride the wave of oil’s resurgence and tuck away a few “lottery ticket” investments like Hemostemix for diversification. It’s a strategy that acknowledges a simple truth: the best portfolios often blend solid blue-chip plays with a dash of speculative spice. In a market sizzling with energy, don’t overlook the alternative route – it just might offer a different kind of sizzle when you need it most.

Disclosure: The above article is for informational purposes and should not be taken as investment advice. Always conduct your own due diligence or consult a financial advisor before making investment decisions, especially in volatile sectors like commodities and biotechnology.

HEMOSTEMIX DISCLAIMER: Disclosure: Lusso’s News, LLC(“EMV”) has been compensated by Hemostemix Inc. (“Hemostemix”) in the amount of $5,000 USD per month, commencing August 13, 2025, and continuing through September 31, 2025, with the possibility of extension until further notice. This compensation is for the creation and dissemination of content about Hemostemix, including but not limited to articles, website postings, social media updates, and other promotional materials.
The content produced by EMV is intended solely for informational purposes. It does not constitute an offer to sell, a solicitation to buy, or a recommendation regarding any security, investment product, or trading strategy. EMV is not a registered investment adviser or broker-dealer, and nothing in this content should be construed as personalized investment advice.
Investing in securities involves risks, including the potential loss of principal. Readers should conduct their own independent research, perform due diligence, and consult with a licensed financial adviser, attorney, or tax professional before making any investment decisions.
EMV’s compensation from Hemostemix presents a conflict of interest as EMV has a financial incentive to promote Hemostemix. As a result, the content may be biased and should not be relied upon as independent or impartial.
By accessing this content or the associated website, you acknowledge and agree to the terms of this disclaimer.